Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716586 · ClinicalTrials.gov registry record · Phase 4
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
A Phase 4 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT00716586 is a Phase 4 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 44 participants.
The verdict
NCT00716586, a Phase 4 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina. Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision. This study will test the use of a topically applied form of this treatment to the eye to reduce the amount of fluid and improve or preserve vision.
Interventions
- DRUG 2% dorzolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2005-10 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716586
The ClinicalTrials.gov registry entry for NCT00716586 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2% dorzolamide is the first listed.
NCT00716586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716586 about?
NCT00716586 is a clinical study titled "Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration". A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina. Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision. This study will test the use of a topically applied form of this treatment t...
What is the current status of trial NCT00716586?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2005-10. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT00716586?
The interventions under investigation include: 2% dorzolamide (DRUG).
Who is sponsoring clinical trial NCT00716586?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.